Hospital

Moderate-to-severe TBI significantly increases the risk of malignant brain tumors, highlighting the need for long-term monitoring in survivors.

Abemaciclib significantly enhances overall survival in high-risk HR+, HER2- early breast cancer, establishing a new standard of care.

Subcutaneous bortezomib shows fewer adverse effects in multiple myeloma treatment compared with intravenous administration, enhancing patient outcomes.

Vaccination is vital for adults with heart disease to prevent severe respiratory illnesses like RSV, influenza, and COVID-19, enhancing overall health outcomes.

Rilzabrutinib gained FDA approval as the first BTK inhibitor for chronic immune thrombocytopenia, offering new hope for patients with persistent symptoms.

Research shows that individuals who use cannabis to self-medicate, especially those with a history of childhood trauma, face heightened risks of paranoia and adverse mental health outcomes.

Future research should focus on optimizing drug design, mitochondrial biogenesis regulation, and establishment of treatments for acute kidney injury (AKI).

An international BMJ panel recommended broader use of SGLT-2 inhibitors and GLP-1 receptor agonists.

The FDA has approved a ready-to-use long-acting injectable formulation that is administered every 3 months as a treatment for advanced prostate cancer.

Abemaciclib enhances overall survival in high-risk HR+, HER2– early breast cancer, establishing its role as a standard adjuvant therapy.

An immunomodulatory nanoparticle called Agg-CLNP has been shown to effectively prevent disease onset for rheumatoid arthritis (RA).

Patients with severe COVID-19 who tested positive for Streptococcus pneumoniae had higher mortality rates.

Drug shortages challenge US health care, driven by systemic issues like low pricing and manufacturing concentration, impacting patient care and safety.

COVID-19 vaccination significantly reduces the risk of asthma and other airway inflammatory diseases, offering vital protection against respiratory complications.

Orforglipron is an effective treatment, leading to significant body weight reduction and improved glycemic control.

Young adults who had experienced an acute myocardial infarction and lived in marginalized communities had increased risks of adverse events and reduced visits to their physician or cardiologist.

The action is significant for patients with extensive-stage small cell lung cancer (SCLC), a population with limited treatment options.

The sensor detects acetone levels in the breath to indicate diabetes.

A novel shingles vaccine candidate demonstrated positive top-line results of antibody and CD4⁺ T-cell vaccine responses.

When treating patients with bone metastases, the biosimilar demonstrated equivalent safety and efficacy to its reference product.

A better understanding of the activation of amylin receptors is a step forward for developing new drugs.

RSV causes a significant burden of acute respiratory infections in older adults.

The study results could help bolster metformin as a potentially attractive option for patients with HER2-positive breast cancer.

The oral glucagon-like peptide agonist-1 met its primary end point and all secondary end points in a randomized, double-blind, placebo-controlled clinical trial for weight management.

Ibrutinib combined with venetoclax significantly improved measurable residual disease and progression-free survival in patients with chronic lymphocytic leukemia.

The FDA approves donidalorsen, the first RNA-targeted therapy for hereditary angioedema, offering significant attack reduction and convenient administration.

New research uncovers complex inflammatory pathways driving asthma flare-ups in children, highlighting the need for personalized treatment strategies.

New research uncovers a pathway linking diabetes and heightened blood clot risks, paving the way for innovative treatments to prevent cardiovascular complications.